Summary:
- The article reports on positive Phase 3 clinical trial results for Eylea (aflibercept) injection 8 mg, a treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
- The trial demonstrated that the 8 mg dose of Eylea was non-inferior to the currently approved 2 mg dose in improving visual acuity in patients with wet AMD and DME.
- The positive results suggest that the higher 8 mg dose of Eylea could provide an additional treatment option for patients with these serious eye conditions, potentially offering improved efficacy and longer treatment intervals.